Natera to Participate in Upcoming Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, announced participation in two significant conferences.
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, announced participation in two significant conferences. Alexey Aleshin, MD, will join a panel at the BTIG Virtual MedTech Conference on February 18, 2021, at 10:00 a.m. PT. Additionally, Steve Chapman, CEO, and Mike Brophy, CFO, will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 11:20 a.m. PT. Live webcasts will be available at investor.natera.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NTRA
The recorded move for NTRA in the trading session of this news was -0.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Feb. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Alexey Aleshin, MD, Natera's Senior Medical Director of Oncology, will participate in a panel discussion at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference. Additionally, Steve Chapman, CEO, and Mike Brophy, CFO, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference.
Details are as follows:
BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference | |
Date: | Thursday, February 18, 2021 |
Time: | 10:00 a.m. PT (1:00 p.m. ET) |
10th Annual SVB Leerink Global Healthcare Conference | |
Date: | Friday, February 26, 2021 |
Time: | 11:20 a.m. PT (2:20 p.m. ET) |
Access to the live webcasts will be available at investor.natera.com.
About Natera
Natera is a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.
Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/natera-to-participate-in-upcoming-investor-conferences-301226652.html
SOURCE Natera, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.